Search by conditions:

 

Protocol Description Phase
16-054 Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma and the Longterm Follow-up of Subjects Treated with bb2121  (View details on clinicaltrial.gov) Phase I
15-105 1205-01: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas  (View details on clinicaltrial.gov) Phase I
16-030 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)  (View details on clinicaltrial.gov) Phase II
14-135 A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor(FGF/FGFR)- Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors or Multiple Myeloma FGF/FGFR-Related Abnormalities  (View details on clinicaltrial.gov) Phase II
14-004 A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastroesophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer  (View details on clinicaltrial.gov) Phase I
14-537 A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies  (View details on clinicaltrial.gov) Phase I
14-389 A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)  (View details on clinicaltrial.gov) Phase I
16-301 A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Refractory Metastatic Anal Cancer  (View details on clinicaltrial.gov) Phase II
15-096 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy  (View details on clinicaltrial.gov) Phase II
15-398 A Multicenter Phase II Clinical Trial of Lubrinectedin (PM01183) In Selected Advanced Solid Tumors.  (View details on clinicaltrial.gov) Phase II
12-274 A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-497 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-140 A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase I
17-274 A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD)  (View details on clinicaltrial.gov) N/A
16-377 A Multicenter, Open-label, Phase 1B Clinical Study of CMP-001 in combination with Pembrolizumab in Subjects with Advanced Melanoma  (View details on clinicaltrial.gov) Phase I
17-018 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-438 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-367 A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (ARAMIS)  (View details on clinicaltrial.gov) Phase III
16-393 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-421 A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects with Relapsed or Refractory B-Cell Non-Hodgkins's Lymphoma  (View details on clinicaltrial.gov) Phase I
15-522 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
15-446 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and pharmacodynamics of AMG 224 in Subjects with Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
16-026 A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-456 A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination with Other Agents in Advanced Cancer  (View details on clinicaltrial.gov) Phase I
17-241 A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity  (View details on clinicaltrial.gov) Phase I
16-359 A phase 1 study of SGN-CD123A in patients with relapsed or refractory acute myeloid leukemia (AML)  (View details on clinicaltrial.gov) Phase I
17-236 A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-002 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-246 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 TsOH as a Single Agent in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-076 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase I
14-524 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma  (View details on clinicaltrial.gov) Phase I
15-404 A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)  (View details on clinicaltrial.gov) Phase I
15-527 A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation  (View details on clinicaltrial.gov) Phase I
11-217 A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fcoptimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3  (View details on clinicaltrial.gov) Phase I
16-534 A Phase 1, Open-Label, Dose Escalation Study of Intravenous Administration of Single Agent BTP-114 in Patients with Advanced Solid Tumors and a Known Deleterious BRCA or DNA Repair Mutation  (View details on clinicaltrial.gov) Phase I
15-577 A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN0158 in Adult Patients with KIT Positive Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-611 A Phase 1, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-229 A Phase 1, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects with High Risk (IPI 3 Or More) Previously Untreated Diffuse Large B-Cell Lymphoma or Grade 3B Follicular Lymphoma  (View details on clinicaltrial.gov) Phase I
16-008 A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-308 A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies  (View details on clinicaltrial.gov) Phase I
16-526 A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer  (View details on clinicaltrial.gov) Phase I
15-207 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma  (View details on clinicaltrial.gov) Phase II
15-471 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-242 A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia  (View details on clinicaltrial.gov) Phase II
15-576 A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
13-474 A Phase 1/2 Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase II
16-143 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
16-379 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-142 A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy  (View details on clinicaltrial.gov) Phase I
17-028 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)  (View details on clinicaltrial.gov) Phase II
16-586 A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors  (View details on clinicaltrial.gov) Phase II
14-271 A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alterations  (View details on clinicaltrial.gov) Phase I
16-450 A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing advanced cancers, including gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung.  (View details on clinicaltrial.gov) Phase II
16-183 A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors  (View details on clinicaltrial.gov) Phase I
17-197 A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal or Gastric Cancer  (View details on clinicaltrial.gov) Phase I
16-154 A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma  (View details on clinicaltrial.gov) Phase I
16-714 A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor  (View details on clinicaltrial.gov) Phase I
16-132 A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)  (View details on clinicaltrial.gov) Phase I
16-096 A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY-241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-395 A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-505 A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin or Pembrolizumab in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer  (View details on clinicaltrial.gov) Phase I
16-472 A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2  (View details on clinicaltrial.gov) Phase I
17-243 A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)  (View details on clinicaltrial.gov) Phase I
13-562 A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) In Combination with Crizotinib (PF-02341066) in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-057 A Phase 1b/2 Open-label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy  (View details on clinicaltrial.gov) Phase II
16-502 A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
16-399 A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-343 A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
15-523 A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)  (View details on clinicaltrial.gov) Phase II
16-258 A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer  (View details on clinicaltrial.gov) Phase II
15-322 A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma  (View details on clinicaltrial.gov) Phase II
14-332 A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma  (View details on clinicaltrial.gov) Phase II
15-226 A Phase 1B/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients  (View details on clinicaltrial.gov) Phase II
16-383 A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase II
16-019 A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor  (View details on clinicaltrial.gov) Phase II
17-044 A Phase 2 Study of lamivudine in patients with p53 mutant metastatic colorectal cancer  (View details on clinicaltrial.gov) Phase II
15-295 A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-566 A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
16-220 A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), In Patients with Advanced Cutaneous Squamous Cell Carcinoma  (View details on clinicaltrial.gov) Phase II
16-505 A Phase 2 Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia  (View details on clinicaltrial.gov) Phase II
16-239 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)  (View details on clinicaltrial.gov) Phase II
16-069 A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia  (View details on clinicaltrial.gov) Phase II
16-340 A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)  (View details on clinicaltrial.gov) Phase II
16-296 A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer  (View details on clinicaltrial.gov) Phase II
16-484 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)  (View details on clinicaltrial.gov) Phase II
15-571 A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency  (View details on clinicaltrial.gov) Phase II
16-322 A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients with MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer  (View details on clinicaltrial.gov) Phase II
16-171 A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)  (View details on clinicaltrial.gov) Phase III
15-291 A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies  (View details on clinicaltrial.gov) Phase II
14-059 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07  (View details on clinicaltrial.gov) Phase III
16-034 A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation  (View details on clinicaltrial.gov) Phase III
16-302 A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy  (View details on clinicaltrial.gov) Phase III
16-209 A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta®) Versus Sunitinib (Sutent®) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma  (View details on clinicaltrial.gov) Phase III
17-114 A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase III
17-178 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab  (View details on clinicaltrial.gov) Phase III
12-487 A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors  (View details on clinicaltrial.gov) Phase I
12-283 A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
06-068 A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066. A CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer  (View details on clinicaltrial.gov) Phase I
13-581 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Previously Treated Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
13-348 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma  (View details on clinicaltrial.gov) Phase I
15-467 A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma  (View details on clinicaltrial.gov) Phase I
14-455 A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors  (View details on clinicaltrial.gov) Phase I
12-306 A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients  (View details on clinicaltrial.gov) Phase I
15-023 A Phase I Trial Of Intensity-modulated Radiation Therapy Using A Contralateral Esophagus Sparing Technique In Locally Advanced Non-Small Cell Lung Cancer and Limited-Stage Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
16-067 A Phase I, First in Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
13-251 A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov) Phase I
15-268 A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation.  (View details on clinicaltrial.gov) Phase I
15-417 A Phase I, Multicenter, Open-Label, Two-Part, Dose-Escalation Study of RAD1901 in Post-Menopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-129 A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands  (View details on clinicaltrial.gov) Phase I
14-263 A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients with Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer  (View details on clinicaltrial.gov) Phase I
15-074 A Phase I, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitbine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-084 A Phase I, Two-Part, Multi-Center, Non-Randomized, Open-Label, Multiple Dose First-in-Human Study of DS-6051b, an Oral ROS1 and NTRK Inhibitor, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-502 A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase II
12-537 A Phase I/IB Study of Ipilimumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation  (View details on clinicaltrial.gov) Phase I
16-139 A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy  (View details on clinicaltrial.gov) Phase I
16-217 A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors  (View details on clinicaltrial.gov) Phase II
13-541 A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers  (View details on clinicaltrial.gov) Phase II
15-542 A Phase I/II Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas  (View details on clinicaltrial.gov) Phase II
15-055 A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients with Advanced, ALK-Positive, Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-464 A Phase I/II, Multicenter, Open-label Study of FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression  (View details on clinicaltrial.gov) Phase II
15-283 A Phase IB Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia  (View details on clinicaltrial.gov) Phase I
15-346 A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers  (View details on clinicaltrial.gov) Phase II
13-313 A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
16-425 A Phase Ib/II Rescue Study With Azacitidine, Durvalumab (MEDI4736), and Tremelimumab Combination Therapy in Recurrent or Metastatic SCCHN Subjects Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy  (View details on clinicaltrial.gov) Phase II
17-112 A Phase IB/II Study of Alectinib Combined with Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC  (View details on clinicaltrial.gov) Phase II
13-367 A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-233 A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer  (View details on clinicaltrial.gov) Phase I
15-454 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors  (View details on clinicaltrial.gov) Phase II
16-104 A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)  (View details on clinicaltrial.gov) Phase II
15-448 A phase II evaluation of Afatinib, an irreversible human epidermal growth factor receptor 2 (Her2/neu) tyrosine kinase inhibitor, in patients with persistent or recurrent HER2-positive uterine serous carcinoma  (View details on clinicaltrial.gov) Phase II
14-328 A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy  (View details on clinicaltrial.gov) Phase II
15-012 A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, To Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations  (View details on clinicaltrial.gov) Phase II
16-118 A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
15-475 A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
14-296 A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia  (View details on clinicaltrial.gov) Phase II
16-248 A Phase II Study of Lorlatinib (PF-06463922) in Advanced ALK and ROS1 Rearranged NSCLC with CNS Metastasis in the Absence of Measurable Extracranial Lesions  (View details on clinicaltrial.gov) Phase II
16-293 A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer  (View details on clinicaltrial.gov) Phase II
16-072 A Phase II Study of Ramucirumab in Patients with Advanced, Progressive Carcinoid Tumors  (View details on clinicaltrial.gov) Phase II
16-138 A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase II
16-263 A Phase II Study With A Safety Lead-In Of Nivolumab In Combination With Bevacizumab For The Treatment Of Relapsed Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer  (View details on clinicaltrial.gov) Phase II
14-370 A Phase II Trial of Integrating Stereotactic Body Radiation Therapy with Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
16-609 A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma  (View details on clinicaltrial.gov) Phase II
04-188 A Phase II Trial of Proton Radiation for the Treatment of Pediatric Rhabdomyosarcoma  (View details on clinicaltrial.gov) Phase II
15-512 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma  (View details on clinicaltrial.gov) Phase II
15-387 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non small cell lung cancer (NSCLC)  (View details on clinicaltrial.gov) Phase II
13-103 A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations  (View details on clinicaltrial.gov) Phase II
14-126 A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib.  (View details on clinicaltrial.gov) Phase II
15-719 A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid  (View details on clinicaltrial.gov) Phase III
17-172 A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)  (View details on clinicaltrial.gov) Phase III
15-331 A Phase III, Open-label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation As Adjuvant Therapy in Patients with PD-L1-Selected, High-risk Muscle-Invasive Bladder Cancer After Cystecomy  (View details on clinicaltrial.gov) Phase III
15-191 A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy  (View details on clinicaltrial.gov) Phase III
17-117 A Phase lb, open-label, multicenter study of oral LXH254 in combination with oral L TT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
12-436 A Pilot Safety Study of Vaccination with Autologous, Lethally Irradiated Colorectal Cancer cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor in patients with Stage IV colorectal cancer  (View details on clinicaltrial.gov) N/A
16-193 A pilot study of Ga-68-DOTA-TOC imaging in participants with small bowel carcinoid tumors.  (View details on clinicaltrial.gov) N/A
14-421 A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated with Chemoradiation or Immunotherapy  (View details on clinicaltrial.gov) N/A
16-551 A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma  (View details on clinicaltrial.gov) Phase II
16-256 A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation  (View details on clinicaltrial.gov) Phase II
16-552 A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma  (View details on clinicaltrial.gov) Phase III
17-135 A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)  (View details on clinicaltrial.gov) Phase III
12-258 A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations  (View details on clinicaltrial.gov) Phase II
12-217 A randomized placebo-controlled phase II trial of irradiated, adenovirus vector transfected GM-CSF secreting autologous leukemia cell vaccination (GVAX) versus placebo vaccination in patients with advanced MDS/AML after allogeneic hematopoietic stem cell transplantation  (View details on clinicaltrial.gov) Phase II
16-244 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy  (View details on clinicaltrial.gov) Phase III
17-120 A Randomized, Double-blind, Placebo-controlled Phase III Study of ODM-201 versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer  (View details on clinicaltrial.gov) Phase III
16-197 A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer  (View details on clinicaltrial.gov) Phase III
15-030 A Randomized, Multi-center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease  (View details on clinicaltrial.gov) Phase III
16-186 A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant  (View details on clinicaltrial.gov) Phase II
16-410 A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (Javelin Ovarian 100)  (View details on clinicaltrial.gov) Phase III
17-707 A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease  (View details on clinicaltrial.gov) Phase II
10-106 A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)  (View details on clinicaltrial.gov) Phase III
15-554 A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)  (View details on clinicaltrial.gov) Phase III
16-550 A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients with Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment with a Safety Lead-in [SNDX-275-0603]  (View details on clinicaltrial.gov) Phase II
16-563 A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation  (View details on clinicaltrial.gov) Phase II
14-375 A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
17-035 A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease  (View details on clinicaltrial.gov) Phase II
17-007 A single-arm, phase II study of neoadjuvant MPDL3280A, nab-paclitaxel and carboplatin (MAC) in resectable non-small cell lung cancer  (View details on clinicaltrial.gov) Phase II
16-598 A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease  (View details on clinicaltrial.gov) Phase II
15-596 A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase II
13-322 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using [11C]Temozolomide PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
13-482 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using FMISO PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
15-715 A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations  (View details on clinicaltrial.gov) Phase II
15-701 A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase III
15-700 A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)  (View details on clinicaltrial.gov) N/A
14-233 Adcetris (Brentuximab Vedotin) Substitution Vincristine in the OEPA/COPDAC Regimen [Treatment Group 3 (TG3 of Euro-Net C1] with Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
16-723 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)- A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers  (View details on clinicaltrial.gov) Phase III
11-464 Afatinib Sequenced with Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial.  (View details on clinicaltrial.gov) Phase II
16-370 An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer  (View details on clinicaltrial.gov) Phase II
13-505 An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS Mutation-Positive Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-403 An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
17-180 An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer  (View details on clinicaltrial.gov) Phase I
16-212 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
16-556 An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)  (View details on clinicaltrial.gov) Phase II
15-212 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy  (View details on clinicaltrial.gov) Phase I
16-326 An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia  (View details on clinicaltrial.gov) Phase I
15-435 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2)  (View details on clinicaltrial.gov) Phase II
17-153 An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients with Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Failed Standard Treatments  (View details on clinicaltrial.gov) Phase I
17-251 An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors  (View details on clinicaltrial.gov) Phase I
16-269 An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma  (View details on clinicaltrial.gov) Phase I
13-615 An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov) Phase II
14-569 An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
11-010 An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-530 An Open-label, Phase Ib/II Clinical Trial of CDK 4/6 Inhibitor, Ribociclib (LEE011), in Combination with Trastuzumab or TDM-1 for Advanced/Metastatic HER2-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase II
16-352 An open-label, pilot study of combination therapy with dabrafenib (GSK2118463) and trametinib (GSK1120212) in patients with relapsed multiple myeloma  (View details on clinicaltrial.gov) N/A
16-108 An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase II
16-200 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)  (View details on clinicaltrial.gov) Phase II
12-188 BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies  (View details on clinicaltrial.gov) Phase III
13-453 BMT CTN 1102: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome  (View details on clinicaltrial.gov) Phase III
12-134 CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide  (View details on clinicaltrial.gov) Phase III
10-327 CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
08-207 Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy  (View details on clinicaltrial.gov) N/A
12-211 COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)  (View details on clinicaltrial.gov) Phase III
15-032 COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)  (View details on clinicaltrial.gov) Phase III
07-125 COG ACNS0332: A Phase III Study Investigating the Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients  (View details on clinicaltrial.gov) Phase III
09-379 COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma  (View details on clinicaltrial.gov) Phase III
14-449 COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma  (View details on clinicaltrial.gov) Phase III
10-239 COG-ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years  (View details on clinicaltrial.gov) Phase III
16-406 Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)  (View details on clinicaltrial.gov) N/A
14-037 Dose reduction of preoperative radiotherapy in myxoid liposarcoma  (View details on clinicaltrial.gov) Phase II
15-709 E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults  (View details on clinicaltrial.gov) Phase III
15-702 E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein  (View details on clinicaltrial.gov) Phase III
16-547 Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism  (View details on clinicaltrial.gov) Phase III
12-307 Evaluation of PET/MRI in Children with Cancer  (View details on clinicaltrial.gov) N/A
14-520 Exploration of Activity of RAD001 in Vestibular Schwannomas and Meningiomas: An NF2 Therapeutic Development Consortium Trial  (View details on clinicaltrial.gov) N/A
16-195 Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women with ER-positive, HER2-negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase II
16-131 FORWARD1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α−positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer  (View details on clinicaltrial.gov) Phase III
12-452 GOG-0279:Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC#613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva  (View details on clinicaltrial.gov) Phase II
17-208 GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease  (View details on clinicaltrial.gov) Phase III
10-218 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma  (View details on clinicaltrial.gov) Phase II
09-273 HOD08: Reduced Duration Stanford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
16-443 Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)  (View details on clinicaltrial.gov) Phase II
13-428 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis  (View details on clinicaltrial.gov) Phase III
16-718 Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma  (View details on clinicaltrial.gov) N/A
16-750 Molecular Analysis for Therapy Choice (MATCH)  (View details on clinicaltrial.gov) Phase II
15-358 Multicenter Phase II, Double-Blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
12-023 NCCTG-N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision  (View details on clinicaltrial.gov) Phase III
17-021 Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
14-242 Non-Comparative, Two-Cohort, Single Arm, Open-label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)  (View details on clinicaltrial.gov) Phase II
15-423 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS- 936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors  (View details on clinicaltrial.gov) Phase II
13-195 Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial  (View details on clinicaltrial.gov) Phase II
15-708 NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-710 NRG-GI001: Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma  (View details on clinicaltrial.gov) Phase III
15-157 Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
15-306 Open-Label, Multicenter, Dose Escalation Phase IB Study with Expansion Phase to Evaluate the Safety, Pharmacokinetics and Activiity of RO5509554 and MPDL3280A Administered in Combination in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
12-466 Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on clinicaltrial.gov) Phase II
16-542 Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy  (View details on clinicaltrial.gov) Phase III
15-318 Oral ONC201 in Adult Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-488 PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase III
16-704 Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)  (View details on clinicaltrial.gov) Phase III
11-318 Phase 1, Multicenter, Open-label, Dose-escalation Study of ACE-011 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
16-150 Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers  (View details on clinicaltrial.gov) Phase I
15-550 Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer  (View details on clinicaltrial.gov) Phase II
16-501 Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies  (View details on clinicaltrial.gov) Phase II
16-272 Phase 1/2 Study of Autologous T-Lymphocytes with Antibody-Dependent Cell Cytotoxicity in Patients with Relapsed or Refractory CD20-Positive B Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
15-436 Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
16-210 Phase 1b Study to Assess The Safety, Tolerability, And Clinical Activity of Gedatolisib In Combination With Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)  (View details on clinicaltrial.gov) Phase I
15-479 Phase 1b/2, Open-label, Dose-finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Of Avelumab (msb0010718c) in Combination with Either Crizotinib or Pf-06463922 in Patients with Advanced or Metastatic Non-small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
16-574 Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) plus Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia  (View details on clinicaltrial.gov) Phase II
14-412 Phase 2 study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients with Glioblastoma (GBM)  (View details on clinicaltrial.gov) Phase II
17-107 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase III
16-358 Phase I dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Gliomas  (View details on clinicaltrial.gov) Phase I
14-213 Phase I Dose Escalation Study of Velcade in Combination with Lenalidomide in Patients with Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation  (View details on clinicaltrial.gov) Phase I
12-267 Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)  (View details on clinicaltrial.gov) Phase I
14-186 Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients With BRAF-Mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-200 Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults  (View details on clinicaltrial.gov) Phase I
13-115 Phase I Study of Olaparib and Temozolomide in Adult Patients with Recurrent/Metastatic Ewing's Sarcoma following failure of prior chemotherapy  (View details on clinicaltrial.gov) Phase I
16-464 Phase I study of Regorafenib in Patients with Advanced Myeloid Malignancies  (View details on clinicaltrial.gov) Phase I
17-078 Phase I Study of Venetoclax plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas  (View details on clinicaltrial.gov) Phase I
13-040 Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov) Phase I
16-004 Phase I, Multicenter, Open-Label, Clinical and Pharmacokinetics Study of PM01183 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-171 Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck  (View details on clinicaltrial.gov) Phase II
13-424 Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-121 Phase I/II Study of Olaparib and Temozolomide in Patients with Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy  (View details on clinicaltrial.gov) Phase II
12-100 Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas  (View details on clinicaltrial.gov) Phase II
15-024 Phase Ib dose-escalation trial of Taselisib (GDC-0032) in combination with anti-HER2 therapies in participants with advanced HER2+ Breast Cancer  (View details on clinicaltrial.gov) Phase I
16-423 Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)  (View details on clinicaltrial.gov) Phase I
17-231 Phase Ib/II Study of TAS-102 plus radiation therapy for the treatment of the liver in patients with hepatic metastases from colorectal cancer  (View details on clinicaltrial.gov) Phase II
17-037 Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase II
14-056-RISK Phase II Double-Blind Randomized Controlled Trial of Naltrexone for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-407 Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma  (View details on clinicaltrial.gov) Phase II
15-005 Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis  (View details on clinicaltrial.gov) Phase II
10-439 Phase II Study of Proton Radiation Therapy for Low Grade Gliomas  (View details on clinicaltrial.gov) Phase II
13-443 Phase II Study of Proton Radiation Therapy for Neuroblastoma  (View details on clinicaltrial.gov) Phase II
12-456 Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors  (View details on clinicaltrial.gov) Phase II
13-249 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults  (View details on clinicaltrial.gov) Phase II
16-136 Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases from Melanoma  (View details on clinicaltrial.gov) Phase II
14-140 Phase II Trial of Natalizumab (Tysabri) plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract  (View details on clinicaltrial.gov) Phase II
16-254 Phase II Trial of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway  (View details on clinicaltrial.gov) Phase II
16-153 Phase II Trial of Pembrolizumab in Central Nervous System Metastases from Multiple Histologies  (View details on clinicaltrial.gov) Phase II
16-155 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the treatment of Oropharyngeal Cancer of the Head and Neck  (View details on clinicaltrial.gov) Phase III
16-386 Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinumcontaining Line (ATLANTIS Trial)  (View details on clinicaltrial.gov) Phase III
11-497 Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Low-intermediate Risk Prostate Cancer  (View details on clinicaltrial.gov) Phase III
10-269 Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix with Metastases to Regional Lymph Nodes  (View details on clinicaltrial.gov) N/A
14-333 Pilot Study of EGFR Inhibition with Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma  (View details on clinicaltrial.gov) N/A
16-513 PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246  (View details on clinicaltrial.gov) Phase II
16-188 Pragmatic Phase III Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  (View details on clinicaltrial.gov) Phase III
16-328 Prevention of gastrointestinal toxicity from total body irradiation or high dose chemotherapy with Pasireotide  (View details on clinicaltrial.gov) N/A
16-728 Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme  (View details on clinicaltrial.gov) Phase II
15-185 Randomized Phase II Study Comparing Selumetinib to Placebo for Enhancing the Clinical Efficacy of Radioactive Iodine (RAI) for RAI-Avid Recurrent/Metastatic Thyroid Cancers Uptake  (View details on clinicaltrial.gov) Phase II
16-705 Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas  (View details on clinicaltrial.gov) Phase II
15-706 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma  (View details on clinicaltrial.gov) Phase II
15-287 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib  (View details on clinicaltrial.gov) Phase III
16-093 Rapid plasma genotyping for early initiation of erlotinib in EGFR mutant lung cancer  (View details on clinicaltrial.gov) Phase II
10-040 RTOG 0926: A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Restaging  (View details on clinicaltrial.gov) Phase II
13-295 RTOG 1112: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase III
14-268 RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC  (View details on clinicaltrial.gov) Phase III
15-469 Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients with Laryngeal, Tracheal and/or Pulmonary Involvement  (View details on clinicaltrial.gov) Phase II
14-416 SWOG 1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (LUNG-MAP)  (View details on clinicaltrial.gov) Phase III
14-409 The Impact of HER2 Heterogeneity on the Treatment of Early-Stage HER2-Positive Breast Cancer: A Phase II Study of T-DM1 in Combination with Pertuzumab in the Preoperative Setting  (View details on clinicaltrial.gov) Phase II
16-320 TRINITI-1: A Phase I/II, single arm, open-label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor  (View details on clinicaltrial.gov) Phase I
308 clinical trials listed

Back to Top